Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05805605 · ClinicalTrials.gov registry record · Phase 2
Allo HSCT Using RIC and PTCy for Hematological Diseases
A Phase 2 study of Myelodysplastic Syndromes and Acute Myelogenous Leukemia, sponsored by Masonic Cancer Center, University of Minnesota.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT05805605: Recruiting Phase 2 study of Myelodysplastic Syndromes and Acute Myelogenous Leukemia, sponsored by Masonic Cancer Center, University of Minnesota.
NCT05805605 is a Phase 2 study of Myelodysplastic Syndromes and Acute Myelogenous Leukemia that is actively recruiting participants, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 56 participants, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05805605, a Phase 2 study of Myelodysplastic Syndromes and Acute Myelogenous Leukemia, is actively recruiting participants, sponsored by Masonic Cancer Center, University of Minnesota.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion using post-transplant cyclophosphamide (PTCy), sirolimus and MMF GVHD prophylaxis.
Primary Outcome
Number of participants with GVHD grades 2-4 after one year post transplant.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL Peripheral Blood Stem Cell Transplant
- DRUG Allopurinol 300 MG
- BIOLOGICAL Bone Marrow Cell Transplant
Study Locations (1)
Minnesota
- Masonic Cancer Center at University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2023-05-01 |
| Est. Completion | 2028-10-22 |
| Phase | Phase 2 |
What NCT05805605 shows while recruiting
NCT05805605 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (80% lower).
The record links to 10 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT05805605 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT05805605 about?
NCT05805605 is a clinical study titled "Allo HSCT Using RIC and PTCy for Hematological Diseases". This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion using post-transplant cyclophosphamide...
What is the current status of trial NCT05805605?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2023-05-01. Estimated completion is 2028-10-22.
What conditions does trial NCT05805605 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Acute Lymphocytic Leukemia, Plasma Cell Leukemia.
What interventions are being tested in trial NCT05805605?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Peripheral Blood Stem Cell Transplant (BIOLOGICAL), Allopurinol 300 MG (DRUG), Bone Marrow Cell Transplant (BIOLOGICAL).
Who is sponsoring clinical trial NCT05805605?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05805605 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05805605's enrollment target sits among peer trials
56 80th of 173 higher than 94 of 173 other Myelodysplastic Syndromes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelodysplastic Syndromes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 2
-
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
RECRUITING · Phase 2
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Ascorbate in Myelodysplastic Syndrome
RECRUITING · Phase 2
-
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI